Adalimumab for Pediatric Uveitis
(ADAPT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to learn whether children and young adults with well-controlled juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior uveitis can safely take adalimumab (or biosimilar) injections less often while maintaining control of their disease.
The main question it aims to answer is: can adalimumab/biosimilar injections be given less frequently without uveitis (eye inflammation) or arthritis (joint inflammation) returning?
Researchers will compare adalimumab/biosimilar injection schedules of every 2 weeks, 4 weeks, 8 weeks, and 12 weeks to determine how injection frequency affects disease control.
Participants will:
* Take adalimumab/biosimilar injections every 2, 4, 8, or 12 weeks.
* Attend study visits every 6 weeks over 24 weeks, with an additional follow-up visit at 48 weeks for checkups, tests, and questionnaires.
* Keep a diary of how often they take adalimumab/biosimilar and other drugs they take for their uveitis/arthritis.
Who Is on the Research Team?
Nisha Acharya, MD MS
Principal Investigator
University of California, San Francisco
Are You a Good Fit for This Trial?
This trial is for children and young adults with well-controlled juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior uveitis. Participants should already be taking adalimumab or a similar medication to manage their eye inflammation.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Adalimumab/Biosimilar
Trial Overview
The study tests if people with controlled uveitis can safely take adalimumab (or its biosimilar) injections less often—every 2, 4, 8, or 12 weeks—without the disease coming back. Different injection schedules are compared over about one year.
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Active Control
Participants receive adalimumab/biosimilar at their current weight-based dose every 8 weeks for 24 weeks.
Participants receive adalimumab/biosimilar at their current weight-based dose every 4 weeks for 24 weeks.
Participants receive adalimumab/biosimilar at their current weight-based dose every 12 weeks for 24 weeks.
Participants receive adalimumab/biosimilar at their current weight-based dose every 2 weeks for 24 weeks, continuing in accordance with current standard of care practice.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Nisha Acharya
Lead Sponsor
National Eye Institute (NEI)
Collaborator
National Institutes of Health (NIH)
Collaborator
University of California, San Francisco
Collaborator
University of California, Davis
Collaborator
University of California, Los Angeles
Collaborator
Children's Hospital Medical Center, Cincinnati
Collaborator
Children's Mercy Hospital Kansas City
Collaborator
University of Miami
Collaborator
University of Utah
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.